How GLP-1 Drugs May Shrink Dangerous Fat Around the Heart | Research

The takeaway

GLP-1 receptor agonists can reduce epicardial adipose tissue, the inflammatory fat layer around the heart linked to cardiovascular disease progression.

Independent risk factor
Epicardial adipose tissue expansion is recognized as an independent cardiovascular risk factor

What the researchers found

GLP-1 and dual GIP/GLP-1 agonists reduce epicardial adipose tissue volume and inflammatory activity, providing a distinct cardiovascular protection mechanism.

Why it matters

EAT is an independent cardiovascular risk factor — drugs that specifically target this dangerous fat depot offer mechanistic benefits beyond weight loss.

The numbers in context

No specific trial data; reviews mechanistic and imaging studies.

How the study worked

Narrative review of preclinical and clinical evidence on incretin therapy effects on epicardial adipose tissue.

Who was studied

Patients with type 2 diabetes, obesity, and cardiometabolic diseases

What this study cannot tell us

Narrative review — mechanistic evidence is strong but clinical outcome data specifically linked to EAT reduction are limited.

How to read the evidence

Narrative review of mechanistic and clinical evidence — provides a compelling hypothesis supported by multiple lines of evidence.

When this study was published

Published in 2025, synthesizing the latest evidence on incretin effects on cardiac fat.

The bigger picture

This identifies EAT reduction as a specific mechanism for GLP-1 cardiovascular benefits, distinct from general weight loss.

Questions still open

Is EAT reduction the primary driver of GLP-1 cardiovascular benefits?
Can EAT volume be used to monitor treatment response?

Common questions

What is epicardial fat and why does it matter?

Fat surrounding the heart that can become inflammatory in obesity and diabetes, independently increasing risk of heart disease, atrial fibrillation, and heart failure.

Can GLP-1 drugs reduce heart fat?

Yes — evidence shows GLP-1 drugs can shrink epicardial fat and reduce its inflammatory activity, which may explain some of their cardiovascular benefits.

Read the original research

Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review.

Canadian journal of physiology and pharmacology, 103(6), 182-192

View on PubMed ↗Publisher’s paper ↗

Citation

Pop, Andrea S K; Dănilă, Maria D; Giuchici, Silvia; Buriman, Darius G; Lolescu, Bogdan M; Sturza, Adrian; Muntean, Danina M; Lascu, Ana. (2025). Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review.. Canadian journal of physiology and pharmacology, 103(6), 182-192. https://doi.org/10.1139/cjpp-2024-0384